CVS Health Corporation (NYSE:CVS) previous close was $86.44 while the outstanding shares total 1.31B. The firm has a beta of 0.81, a 12-month trailing P/E ratio of 15.27, and a growth ratio of 3.82. CVS’s shares traded lower over the last trading session, losing -0.66% on 06/01/21. The shares fell to a low of $85.2701 before closing at $85.87. Intraday shares traded counted 6.1 million, which was 17.57% higher than its 30-day average trading volume of 7.40M. The stock’s Relative Strength Index (RSI) is 58.27, with weekly volatility at 2.10% and ATR at 1.69. The CVS stock’s 52-week price range has touched low of $55.36 and a $90.61 high.
Investors have identified the Healthcare Plans company CVS Health Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $113.03 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
CVS Health Corporation (CVS) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CVS, the company has in raw cash 5.6 billion on their books with 2.67 billion currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 55.72 billion total, with 60.1 billion as their total liabilities.
CVS were able to record 2.06 billion as free cash flow during the 08/04/2021 quarter of the year, this saw their quarterly net cash flow reduce by -2.22 billion. In cash movements, the company had a total of 2.89 billion as operating cash flow.
Potential earnings growth for CVS Health Corporation (CVS)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/04/2021 quarter of the year, CVS Health Corporation recorded a total of 69.1 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 3.39% coming in sequential stages and their sales for the 08/04/2021 quarter reducing by -0.66%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 40.89 billion trying to sell their products during the last quarter, with the result yielding a gross income of 28.2 billion. This allows shareholders to hold on to 1.31B with the recently reported earning now reading 1.69 cents per share. This is a figure that compared to analyst’s prediction for their 08/04/2021 (2.04 cents a share).
Having a look at the company’s valuation, the company is expected to record 8.16 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CVS sounds very interesting.
Is the stock of CVS attractive?
In related news, EVP & General Counsel, Moriarty Thomas M sold 109,469 shares of the company’s stock in a transaction that recorded on May 10. The sale was performed at an average price of 86.00, for a total value of 9,414,334. As the sale deal closes, the EVP and Chief Medical Officer, Brennan Troyen A now sold 9,477 shares of the company’s stock, valued at 796,068. Also, EVP & CFO, Boratto Eva C sold 4,905 shares of the company’s stock in a deal that was recorded on May 04. The shares were price at an average price of 80.00 per share, with a total market value of 392,400. Following this completion of acquisition, the EVP & General Counsel, Moriarty Thomas M now holds 103,423 shares of the company’s stock, valued at 7,963,571. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
17 out of 29 analysts covering the stock have rated it a Buy, while 9 have maintained a Hold recommendation on CVS Health Corporation. 0 analysts has assigned a Sell rating on the CVS stock. The 12-month mean consensus price target for the company’s shares has been set at $93.58.